TORONTO, ONTARIO--(MARKET WIRE)--Jun 4, 2007 -- Lumonall, Inc. (OTC BB:MLIC.OB - News), formerly Midland International Corp., has secured Midwestern United States distribution for its photoluminescent Exit Signs and Safety Way Guidance Systems through its latest strategic partner, Hallmark Building Supplies, Inc.
Headquartered in Milwaukee, Wisconsin, Hallmark (www.hllmark.com) was founded in 1974 by its current President and CEO, O. Joseph Balthazor. Hallmark is an integrated system of Marketing, Sales, and Distribution of branded building materials to residential and commercial markets, serving ten Midwestern states. Hallmark prides itself in its ability to develop and maintain value-adding relationships with its partners and customers.
"We are excited to be associated with an innovative company like Lumonall, Inc. and its energetic and enthusiastic leadership," announced O. Joseph Balthazor, Hallmark's President and CEO. "With the Lumonall® product line there is great opportunity for growth and we are able to leverage our 'core' capability of creating and fulfilling demand for the Commercial market."
Hallmark Building Supplies, Inc. will be responsible for distributing Lumonall® products to Arkansas, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, South Dakota and Wisconsin.
"We are thrilled to have Hallmark join our Exclusive Distributor network," said Mike Hetherman, President and COO of Lumonall, Inc. today. "Their experience and local market relationships will ensure Lumonall® will be well positioned to service the Midwest. With the addition of Hallmark, we have assembled some of the best distributors in North America, asserting and reinforcing one of our key messages: 'Best By Far.'"
The latest in a string of partnerships, Hallmark (www.hllmark.com) joins the Willis Group of Companies (www.willisgroupofcompanies.com), Designer Building Solutions (www.4dbs.com) and the Butler-Johnson Corporation (www.butler-johnson.com), as part of the Lumonall, Inc. distribution network.
About Lumonall, Inc.
Lumonall, Inc. is a global supplier of innovative photoluminescent (PLM) products, with a current concentration on Exit Signs and Safety Way Guidance Systems (SWGS). A supplier of "green" products and solutions, Lumonall, Inc. focuses first and foremost on Safety, Environmental issues and Cost savings.
The company leverages nearly 20 years of innovation and development in manufacturing, photoluminescent technology, and safety products. Using the company's proprietary PLM formulation, Lumonall, Inc. intends to internationally market low cost, high performance photoluminescent Exit Signs and Safety Way Guidance Systems. The company's core strategy involves strategic alliances with those wishing to purchase licenses for Territories, Fabrication and New Product Development. The company's PLM formulation meets all current building code standards.
-------------------- The difference between genius and stupidity is that genius has its limits
IP: Logged |
posted
SSTP (.059) BioCentric Energy and Core Ventures (BCEI/Core) Announce Joint Venture Agreement With Sustainable Power Corp.
Monday June 4, 4:20 pm ET
HUNTINGTON BEACH, CA--(MARKET WIRE)--Jun 4, 2007 -- BCEI/Core announces today the signing of a Joint Venture Agreement with Sustainable Power Corp. (Other OTC:SSTP.PK - News) to capitalize on their unique Rivera Process of Hydrolysis/Pyrolysis which delivers Cellulosic Ethanol. The first negotiated facilities to deliver this revolutionary solution are in Mason City, Iowa with a projected completion date of first phase by October 15, 2007 and Caruthersville, Missouri with a projected completion date of June 1, 2008.
This unique Rivera Process of Hydrolysis/Pyrolysis is a cost-effective paradigm in the biofuels arena utilizing feedstocks considered to be of low to no value biomass. Jack Tortorice, President of BCEI/Core, stated, "Our team is committed to funding, engineering, build out, onsite management, and the delivery protocol to empower our association to be first to market with a Cellulosic Ethanol Facility. As other biofuel companies suffer from the escalating and prohibitive feedstock pricing, we will be delivering the solution."
About Cellulosic Ethanol: The Federal government, with the assistance and prodding of the White House, has allocated funds for the advancement of engineering, science, and entrepreneurial spirit to deliver energy through low or no value biomass. These feedstocks include, but are not limited to, switch grass, slag from ethanol producers, and auto fluff from auto dismantlers.
About BCEI/Core: The BioCentric Energy Incorporated Team has spent considerable time and treasure in the research and development to deliver Cellulosic Ethanol to our country from low, no or negative value feedstocks. The BCEI focus is on the energy business origination and the outsourcing of the actual technological development, design, engineering, and construction functions of the build out of the facility are entrusted to our partners, Core Ventures. Core has earned the right to be referred to as the most seasoned Biofuel professionals with 31 biofuel facilities on their resumes. They are also well staffed and positioned financially to assume the initial and ongoing risks associated with projects of this size and nature. This combined business focus provides the BCEI/Core Alliance with rapid expansion capabilities, mitigating risk while controlling fixed and variable costs.
About Sustainable Power Corp.
Sustainable Power Corp. is an international green energy service provider focused on environmentally safe power generation. The company has the exclusive rights to develop and manage a portfolio of green power plants utilizing the USSEC biofuel discovery, a renewable fuel source able to be produced from one-fifth of the soybean acreage traditionally associated with biodiesel. For more information please visit www.sustainablepower.com.
-------------------- The difference between genius and stupidity is that genius has its limits
IP: Logged |
posted
CKPY(.20) Wins Prepaid Wireless Telecommunications Contract with Direct Wholesale, Inc. Jun 4, 2007 4:35:00 PM DALLAS, TX -- (MARKETWIRE) -- 06/04/07 -- ClickPay Solutions, Inc. (PINKSHEETS: CKPY) has been selected by Direct Wholesale Inc. as an authorized supplier of prepaid telecommunications products and services. Under the agreement, ClickPay will supply Direct Wholesale with a variety of prepaid wireless telecommunications products for distribution into consumer retail channels. In addition, ClickPay will provide consulting services to improve the efficiency of the company's supply chain.
Matt Waldie, recently appointed as ClickPay's Chief Operating Officer, said, "Our team's hard work in redirecting ClickPay's business model is beginning to pay off. We are excited to bring Direct Wholesale on our platform as a key customer."
About ClickPay Solutions, Inc.
Headquartered in Dallas, TX, ClickPay Solutions, Inc. (PINKSHEETS: CKPY) is an industry leader in distributing and marketing technology products and applications in the wireless telecommunications marketplace. The products sold by ClickPay are distributed through thousands of retail locations nationwide.
About Direct Wholesale Inc.
Headquartered in Red Bank, NJ, Direct Wholesale Inc. is one of the largest wholesalers of prepaid wireless cards and PINs in the U.S. Direct Wholesale also specializes in the distribution of wireless handsets including GSM and CDMA technologies.
Forward-Looking Statement
"Safe Harbor" Statement - Under the Private Securities Litigation Reform Act of 1995, this press release may contain forward-looking statements that involve risks and uncertainties. Important factors, which could cause actual operating results to differ materially from those in the forward-looking statements, are detailed in filings with the Securities and Exchange Commission made from time to time by the Company. This press release and statements are current as of the date of the individual announcements and the Company undertakes no obligation to publicly release any revisions to any forward-looking statement to reflect events or circumstances after the date thereof or to reflect the occurrence of unanticipated events.
Contact: ClickPay Solutions, Inc. Investor Relations Email Contact
-------------------- The difference between genius and stupidity is that genius has its limits
IP: Logged |
posted
PHDT(.19) to change corporate name and Cusip OTC BB symbol (PHDT) MIAMI, June 4 /PRNewswire-FirstCall/ - Phinder Technologies Inc. is pleased to announce the approval of the shareholders to change the corporate name and symbol of the company, at the annual and special meeting held on May 24th, 2007. The new name of the company will be 'Zupintra Corporation, Inc'. (Zupintra Communications, Inc. being a subsidiary of Zupintra Corporation, Inc.)
Phinder has submitted the appropriate documents with the Florida Department of State Corporate Divisions. The company expects to have the new cusip and symbol shortly. Once this change occurs, the company will notify the shareholders further.
Zupintra Communications Inc. Zupintra is a facilities based wholesaler of international voice traffic within the carrier to carrier network. As a wholesale VoIP provider, Zupintra Communications Inc. signs both origination and termination contracts with next generation carriers and profits from negotiated rates.
In compliance with the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, PHDTF notes that statements contained in this announcement that are not historical facts may be forward-looking statements that are subject to a variety of risks and uncertainties. Accordingly, PHDTF wishes to caution readers of this announcement that its future actual results may differ materially from those that any forward-looking statements may imply. There is no assurance the above-described events will be completed. There can be no assurance of the ability of the company to achieve sales goals, obtain contracts or financing, consummate acquisitions or achieve profitability in the future. The above and additional factors are discussed in detail in the company's filings with the U.S. Securities and Exchange Commission. These may be viewed at www.sec.gov and many other Web sites without charge.
posted
ERUC(.35) Signs With PartnerCare ER Urgent Care Centers (PINKSHEETS: ERUC) -- ERUC is proud to announce that it has signed with PartnerCare Health Plans. PartnerCare has over 1,600 members in the State of Florida in nine counties and is adding 13 additional counties throughout Florida in 2007. They currently specialize in Medicare beneficiaries. Being a Physician owned HMO they are dedicated to true continuity of care for their members.
They are an award-winning organization for excellence in healthcare delivery. This organization grew to over 78,000 members in less than two years in Puerto Rico. As a provider for PartnerCare, ER Urgent Care continues to expand its list of insurances accepted in the most significant growth segment of Healthcare. Jerry Miller, Founder, said, "We are very honored to be affiliated with such a formidable organization that is experiencing such growth in one of the largest markets in AMERICA."
About ER Urgent Care
ERUC Management Company Inc. operates ER Urgent Care Centers in the South Florida area. The "true, bona-fide," "Urgent Care Center" is a one-stop-shop where patients can receive premier health care, after-hours, at a fraction of the cost of emergency room visits. With the "Urgent Care Center" model emergency rooms will no longer lose money on ER patients with minor injuries and illnesses and the HMOs will no longer have to pay exorbitant claims for non-admitted patients. ER Urgent Care Centers create a win-win situation for everyone, filling the financial and service gap between primary care physicians (PCPs) and hospital emergency rooms.
700 Ives Dairy Rd. 1601 Meadowlark Lane North Miami Beach, FL 33179 Kansas City, KS 66102
213 North Federal Highway 7208 Sterling Ave. Hallandale Beach, FL 33009 Tampa, FL 33614
15463 SW 137th Ave. Doctors Family Medical Kendal, FL 33177 5535 Memorial Highway Tampa, FL 33634 Doctors Family Medical 2370 International Blvd. Deland, FL 32724 Doctors Family Medical 431 SW Blvd. North 18648 NW 67th Ave St. Petersburg, FL 33703 Miami Lakes, FL 33177
ER Urgent Care Center Tampa ER Urgent Care Center St. Pete 5535 Memorial Highway #101 431 SW Blvd. North Suite A Tampa, FL 33634 St. Petersburg, FL 33703
ER Urgent Care Center is a provider for Amerigroup, Avmed, Humana, Aetna, Medicaid/Medipass/Medi-Kids, Total Health Choice, United Health Care, Beech Street, Dimension Health, Assist Card, Cigna, Corvel, Health Insurance Plans and many more.
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products, which we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.
For franchising and corporate information please contact us toll free at 1-877-303-3500.
posted
SCNI (.22) Announces Final Judgment and Appeal in New York Litigation with ICOS Vision Systems N.V.
Business Wire "US Press Releases "
MINNEAPOLIS--(BUSINESS WIRE)--
Scanner Technologies Corporation (OTCBB:SCNI) announced today that a final judgment has been ordered in its ongoing litigation with ICOS Vision Systems Corporation NV in the U.S. District Court for the Southern District of New York.
In July of 2000, Scanner Technologies Corporation instituted an action against ICOS Vision Systems Corporation N.V. in the U.S. District Court for the Southern District of New York for infringement of two patents (U.S. Patent Nos. 6,064,756 and 6,064,757) owned by Scanner. The patents disclose systems and methods of inspecting ball grid array devices in three dimensions. ICOS later instituted actions against Scanner in 2005 and 2007 asking the court to declare those patents, and other related patents invalid and not infringed.
On June 1, 2007, the New York court entered an order that states Scanner's '756 and '757 patents are not infringed by ICOS and its customers, and Scanner is barred from enforcing all of its patents related to inspecting ball grid array devices in three dimensions. As a result of the ruling, the court dismissed the 2005 and 2007 ICOS actions and ordered ICOS to apply for attorneys' fees and costs by June 18, 2007.
Scanner has filed a notice of appeal in the case.
About Scanner Technologies Corporation:
Scanner is a New Mexico corporation that invents, develops and markets vision inspection products that are used in the semiconductor industry for the inspection of integrated circuits. Scanner's headquarters are located in Minneapolis, Minnesota and has a manufacturing facility in Tempe, Arizona. Scanner's stock is traded on the Over-The-Counter Bulletin Board under the symbol "SCNI." For more information please visit www.scannertech.com.
Source: Scanner Technologies Corporation
-------------------- The difference between genius and stupidity is that genius has its limits
IP: Logged |
posted
VAPH (.095) Minor League Baseball is Major Marketing Hit for VasoActive Topical Lotions
Business Wire "US Press Releases "
DANVERS, Mass.--(BUSINESS WIRE)--
"Why spend extra on mass-media advertising when you can reach almost as large an audience through other vehicles for a small fraction of the cost?" asks Stephen Cataldo, Director of Marketing, VasoActive Pharmaceuticals, Inc. (VAPH.ob) (http://www.vasoactive.us), distributors of uniquely formulated branded topical lotions for temporary relief for minor arthritis, muscle and joint pain, as well as relief from athlete's foot.
VasoActive products include Osteon arthritis pain relieving lotion, A-R Extreme for muscle and joint pain, along with Termin8, proven clinically effective in the treatment of athlete's foot with daily use.
"The combination of limited advertising resources and very specific retail territories demanded that we look for the most affordable way to reach large numbers of people. We decided for Minor League Baseball as a part of our marketing plan in 2006, which happily coincided with the best-ever season the Minor Leagues have ever had. While the plan still is in the early stage of implementation, from early indications we are optimistic that it will produce positive results," said Mr. Cataldo.
According to the Sports Network in October 2006, "Minor League Baseball set an all-time attendance record this season with a total of 39,887,755 fans going through the turnstiles at the 176 teams in the 15 affiliated leagues. That was an increase of 105,038 over the old mark that was set more than a half-century ago and an increase of 818,048 over the 2003 season. The former record was set in 1949 during the boom years following World War II when nearly every city and large town in the United States had its own Minor League team. That total of 39,782,717 was attained by 448 teams in 59 leagues."
"During the 2006 season, VasoActive experimented with promotional campaigns designed to increase visibility to help gain sales momentum," Mr. Cataldo continued. "These minor league ball parks in Michigan, New York, and New Jersey, helped us reach from four to six thousand fans per game."
Mr. Cataldo added, "The promotional campaigns continue in 2007. Last week produced some additional exposure at the home ballpark of the Trenton Thunder. Just in case you folks haven't heard, pitcher Roger Clemens, winner of seven Cy Young Awards, is returning to baseball - and it happens that he is now pitching with the Trenton Thunder AA club, a New York Yankees farm club. Roger Clemens' home game event drew a record of 9,134 fans. Promoting our A-R Extreme product on the Thunder's video scoreboard, with the game televised nationally, gave us a substantial audience that day," explained Mr. Cataldo.
VasoActive products are available through retail outlets including Pathmark in New Jersey and New York, ShopRite, A&P, Super Fresh, Waldbaum's, Harmon Health and Beauty and 140 Meijer stores throughout Illinois, Indiana, Kentucky, Michigan and Ohio. Ordering can also be placed online via Amazon.com.
Unique PENtoCORE(R) Technology Provides High Performance Results
The VasoActive family of topical products features a proprietary technology called PENtoCORE(R), which provides safe, effective topical products with less odor, less greasy feel and no residue. PENtoCORE(R) was developed by VasoActive's parent company, BioChemics, a drug delivery company with more than 15 years of research into topical drug delivery improvements.
About VasoActive
VasoActive began operations in January 2003 as a division of BioChemics (http://www.biochemics.com), a biopharmaceutical company engaged in transdermal and topical drug delivery systems. VasoActive is an early stage company established to commercialize, market and sell over-the-counter pharmaceutical products incorporating vaso active lipid encapsulated technology.
FORWARD-LOOKING STATEMENTS
Certain statements contained herein constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about the Company's industry, management's beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Because such statements involve risks and uncertainties, the actual results and performance of the Company may differ materially from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, the Company also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made here; however, readers should review carefully reports of documents the Company files periodically with the SEC.
Source: VasoActive Pharmaceuticals, Inc.
-------------------- The difference between genius and stupidity is that genius has its limits
IP: Logged |
posted
VEGF (.37) Stockholders Approve Merger with VIA Pharmaceuticals and Related Proposals
PR Newswire "US Press Releases "
ATLANTA, June 4 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. (Nasdaq: VEGF), a development stage company dedicated to the development of innovative products in the life sciences industry, announced today that its stockholders approved the previously announced merger with VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, at its special meeting of stockholders held on June 4, 2007. The transaction, which is subject to customary closing conditions, is expected to close on or about June 5, 2007.
At the special meeting, Corautus stockholders also approved several proposals related to the merger transaction, including amendments to Corautus' charter to increase the authorized shares of common stock to 200,000,000, to effect a reverse stock split of Corautus common stock at a ratio within the range of 1:5 to 1:20, and to change the name of Corautus to "VIA Pharmaceuticals, Inc." following the closing of the merger.
Following the special meeting of stockholders, the Corautus board of directors approved a reverse stock split of the Corautus common stock at a ratio of 1:15. Corautus common stock will begin trading on a reverse split- adjusted basis on June 6, 2007. As a result of the reverse stock split, every 15 shares of Corautus common stock will be combined into one share of Corautus common stock. Corautus will pay cash in lieu of fractional shares in connection with the reverse stock split.
About Corautus Genetics Inc.
Corautus Genetics Inc. is a development stage company dedicated to the development of innovative products in the life sciences industry. Corautus, formerly known as GenStar Therapeutics Corporation and Urogen Corp., was formed as a Delaware corporation on June 30, 1995. Prior to November 1, 2006, Corautus was primarily focused on the clinical development of gene therapy products using a vascular growth factor gene, Vascular Endothelial Growth Factor 2 (VEGF-2), for the treatment of severe cardiovascular disease. Corautus was the sponsor of a Phase IIb clinical trial to study the efficacy of VEGF-2 for the treatment of severe cardiovascular disease, known as the GENASIS trial. For more information, visit: www.corautus.com.
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target inflammation in the blood vessel wall, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. VIA's lead drug candidate, VIA-2291, is in two concurrent Phase II clinical studies in patients with cardiovascular disease. VIA is privately-held and headquartered in San Francisco, CA. For more information, visit: www.viapharmaceuticals.com.
Forward-Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. These risks include statements that address performance, events or developments that we or VIA expect or anticipate will occur in the future, such as the completion of our merger with VIA. These risks are discussed in Corautus Genetics Inc.'s Securities and Exchange Commission filings, including, but not limited to, the risk factors in Corautus' 2006 Annual Report on Form 10-K, which was filed on March 30, 2007, as amended by Corautus' Form 10-K/A for 2006, which was filed on April 30, 2007 and Corautus' Form 10-Q for the period ended March 31, 2007, which was filed on May 15, 2007, all of which are incorporated by reference into this release. All forward-looking statements included in this release are based on information available to Corautus and VIA on the date hereof, and neither Corautus nor VIA assumes any obligation to update any such forward- looking statements.
Contact Information: Corautus Genetics Inc. Jack W. Callicutt Senior Vice President and Chief Financial Officer 404.526.6210
SOURCE Corautus Genetics Inc.
-------------------- The difference between genius and stupidity is that genius has its limits
IP: Logged |
YUCAIPA, Calif., June 5 /PRNewswire-FirstCall/ -- Ingen Technologies, Inc. (OTC: IGTG), a medical device manufacturer, announced today that the new OxyView(R) product has been registered and classified by the Food and Drug Administration. In addition, the company has completed the required SEC filings to be fully compliant with its periodic reporting obligations.
The Company's flagship product, OxyView(R), is now an FDA registered and classified device. OxyView(R) is a proprietary in-line pneumatic flow-meter that provides visual monitoring of oxygen flow-rate for patients in the hospital, surgical room, home oxygen therapy, nursing homes and emergency response facilities as well as provides a use with commercial aviation product manufacturers of oxygen delivery systems. OxyView(R) is a cutting edge product compared to the type of flow meters currently in the market that are dependent on gravity for operation and can only be attached to the regulator or source. OxyView(R) is gravity-independent and can function in any position; it can be attached in-line and within inches of the patient regardless of any source. OxyView(R) is much less expensive, more assessable and more accurate than the flow meters currently in the market. More important, OxyView(R) enhances the safety, assurance and accuracy of oxygen flow for patients being administered oxygen from any source, and unlike all of the other flow meters, OxyView(R) quickly and easily attaches to any cannula close to the patient. OxyView(R) can quickly provide information to the patient regarding proper flow rate or any obstruction between the patient and the source. OxyView(R) can prevent substantial Medicare costs for maintenance and repair of respiratory equipment.
"Ingen has sold thousands of OxyView(R) units since its' introduction last November. Sales have recently increased this 4th quarter (Ingen's fiscal year is May 31 to June 1). We have 12 new distributors in the USA and abroad, and are finalizing negotiations with one of the world's largest distributor of respiratory products. This distributor has requested sole distribution of OxyView(R). We expect to close negotiations this month," said Scott Sand, CEO & Chairman of Ingen Technologies.
There are millions of people each year that require home oxygen therapy, and there are many more who require oxygen during hospitalizations and medical emergencies. This market continues to expand with the growing elderly population. OxyView(R) is sold in the USA, Canada, European Communities, Japan and the People's Republic of China. The company has issued and pending patents in the US, Canada, European Communities, Japan and People's Republic of China.
The Company's Salt Lake City based auditing firm, Child-Van Wagoner- Bradshaw, has completed the remaining audits/reviews for the period from 1999- 2004 and all of the required K-SB and Q-SB documents were filed with the SEC through EDGAR in May-2007. Ingen Technologies, Inc., a Georgia Corporation, was formed as a result of a reverse merger in March 2004 whereby Ingen became a publicly-owned company and commenced trading in the Over-The-Counter market on the Pink Sheets. Ingen (GA) is a holding company which owns intellectual property rights to certain proprietary devices which primarily provide diagnostic and safety features to health practitioners and patients. Operations are conducted through a 100%-owned subsidiary, Ingen Technologies, Inc. of Nevada, which has been in business since 1999 when Chairman/CEO Scott R. Sand founded it. The principal executive office is in Yucaipa, CA, northeast of Los Angeles.
"Although we immediately commenced with our reporting obligations at the time of the 2004 merger, there were no filings done by the previous management of the public company between 1999-2004. This has been our 'Achilles Heal' in being able to move to the OTCBB and file any type of registration to continue funding various new projects. Today Ingen is now current with all of its reporting obligations, and both the OTCBB and filing of future registrations are within close reach," said Thomas Neavitt, CFO of Ingen Technologies.
Scott Sand, CEO further stated: "This is a monumental accomplishment for this company and for our shareholders. We have forged our way through, moving forward steadily and against difficulties, and accomplished building the necessary foundation upon which I believe we can grow a successful and fruitful company with increased earnings and shareholder value. The time has come for Ingen to succeed."
About Ingen Technologies, Inc.
Ingen has devised a business model with some very appealing operational and economic aspects. First, its core strength is obtaining intellectual property rights (owning patents and trademarks) to technologically advanced products, particularly with medical applications for the elderly portion of the population. There, aging increases the incidence of balance and breathing disorders. Second, Ingen out-sources its manufacturing, deliberately avoiding the necessary investment in, and headaches of, manufacturing. Third, in the case of Secure Balance(R), OxyView(R) and OxyAlert(R), the sales function is, and will be, outsourced to organizations with existing marketing channels (and Rolodexes). Again, Ingen escapes something many companies do not -- the costly and time-consuming necessity to create an internal sales force. There is a rational quid pro quo: Ingen gains immediate access to a productive marketing organization; the latter gains equally rapid access to an additional, and attractive, product to pour through its distribution pipeline. Thus, there are mutual -- and major -- economic efficiencies and timesaving, for both parties.
There is a real economic savvy to Ingen's approach in two particular respects. First, overhead expenses are sliced to a minimum: no internal manufacturing or selling. Therefore, a big chunk of any future incremental revenue growth would flow through the income statement to earnings. Second, in the future, Ingen is positioned to add other interesting technologies to its product portfolio, thereby boosting potential revenues and leveraging earnings.
Contact: Scott R. Sand, C.E.O & Chairman Ingen Technologies, Inc. - Administrative Office 35193 Avenue "A", Suite-C Yucaipa, California 92399 Phone: (800) 259-9622 or (909) 790-7180 Fax: (800) 777-1186 or (909) 795-6340 Email: Info*ingen-tech.com
A Member of the Better Business Bureau A Member of the Chamber of Commerce A Licensed Business in the City of Yucaipa
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Paradigm Medical Industries Introduces New Software for P60 UBM DeviceLast update: 6/5/2007 2:35:06 PMSALT LAKE CITY, Jun 05, 2007 (BUSINESS WIRE) -- Paradigm Medical Industries, Inc. (OTCBB: PMED.OB/PMEDW.OB), a leading innovative producer of ultrasound devices for the ophthalmic and medical industries, announced today the introduction and release of a new software package for the P60 Ultrasound BioMicroscope (UBM). Dubbed V2.1, the software has been installed at Massachusetts Eye & Ear Infirmary. The V2.1 software incorporates greater image resolution, a very user-friendly and robust database management system and networking capabilities that allow the patient image data to be transferred within a user's network for efficient patient record management. Software distribution for in-service P60 UBM upgrades will be available worldwide by the end of this month. The P60 UBM is Paradigm Medical's fourth-generation device that is a sophisticated microprocessor-based, multi-frequency Ultrasound BioMicroscope that allows practitioners to acquire and view high-resolution images of the anterior segment of the eye. The P60 is used for imaging of vital structures of the eye, primarily the anterior chamber of the eye. Imaging of the anterior chamber angle is one of the principal areas studied in the detection of closed angle glaucoma pathologies and related surgical filtering. The P60 UBM has been approved by regulatory agencies in the United States, Canada, Western Europe, Middle East, South America, and most of the Pacific Rim. "The V2.1 truly surpasses anything that is already in the market today," said Paradigm Medical's Chief Executive Officer, Raymond Cannefax. "I am extremely satisfied and excited about the functionality and the greatly enhanced features the V2.1 software provides. As the leader in ultrasound biomicroscopy, it is only fitting that Paradigm Medical provides the most robust software available to meet the demands of the industry. The P60 UBM is obviously the Gold Standard, as was the case with the Company's versions of the P40 and P45 UBMs." The V2.1 software was developed by the optic and engineering group at Reliacon Global, Inc. (San Ramon, CA), as part of a partnership with Paradigm Medical that was formed earlier this year. A beta version of the software has been in use at the University of California at San Diego, Hamilton Glaucoma Center and at the Bascom Palmer Eye Institute (Miami, FL). The final version of the software will be loaded onto the P60s at those two facilities as well as onto the UBM at the University of California, San Francisco, by midyear. All P60 customers using Paradigm Medical's original V1.6 version of the software will receive upgrades at no cost. Paradigm Medical Industries, Inc. (Salt Lake City, UT), currently develops, manufactures and markets high-tech, proprietary diagnostic equipment and consumable products for the medical industry. The Company is a leading developer of Ultrasound devices, and has been dubbed "The UBM Company" (Ultrasound BioMicroscope). Contact us at 801-977-8970 or visit us at . This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements. SOURCE: Paradigm Medical Industries, Inc. Paradigm Medical Industries, Inc.Raymond Cannefax, CEO801-977-8970
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
